Microsoft Word - 0 リーフレット序.doc

動物MHC研究会　ニュースレター　創刊号

動 物 MHC 研 究 会 ニュースレター 創 刊 号 創 刊 号 の 内 容 研 究 会 設 立 の 趣 旨 並 びにこれまでの 経 緯 間 陽 子 会 長 挨 拶 間 陽 子 第 1 回 シンポジウムを 振 り 返 って 中 西 照 幸 連 載 : HLA 領 域 椎 名 隆 第 2 回 動 物 MHC シンポジウムのお 知 らせ 事 務 局 からのお 知 らせ 資 料 :1) 動 物 MHC

MHC23-3

Major Histocompatibility Complex 2016; 23 (3): 168 184 1) 2) 3) 4) 5) 1) 6) 7) 8) 1) 2) 3) 4) HLA 5) 6) 7) 8) HLA 11 25 28 10 22 1 4 61 44 6 1 10 11 5 HLA 60 3 27 3 5 9 5 10 19 5 50 22.4 5.9 8.2% 78.7%

DynalTransplantDiagnostic.indd

2011 1 SeCore HLA SBT 1 2 AllSet + Gold SSP HLA 7 3 SSP UniTray HLA 11 4 27 5 32 ii 1 SeCore HLA SBT SeCore 2 SeCore HLA SBT SeCore 3 SeCore 4 HLA-I 5 HLA-II 5 utype 5 GSSP 6 1 SeCore HLA SBT Sequencing

/‚“1/ŒxŒ{‚×›î’æ’¶

60 1 pp.3-8 2010 1. H1N1 1) 2) 3) 4) ERATO 2009 H1N1 21 H1N1 HA PB2 2009 3 Pandemic H1N1 2009 WHO 6 11 21 2009 11 2010 4 21 H1N1 H1N1 2009 4 15 CDC 108-8639 4-6-1 TEL: 03-5449-5281 FAX: 03-5449-5408 E-mail:

表1.eps

Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol

能書単頁9[1].5(2)

ips CytoTune -ips ver.1.0 1 I CytoTune ips 3 II 3 3 4 5 III CytoTune ips ips 6 6 6 6 7 1) 2) ips 8 ips 8 SeV 9 SeV 10 IV Q&A 11 V 12 12 VI...13 13...13 2 I CytoTune ips CytoTune ips 4 OCT3/4SOX2 KLF4c

(1) (1) (2) (3) (4) (1) (2) (3) (4) (1) (2) (3) (4) (5) (6) (7) (1) (1) (2) (3) (1) (2) (3) (4) (1) (2) (3) (4) (5) (1) (2) (3)

(1) (2) (3) (1) Word (2) 1 (3) Excel (4) Excel (5) 2 (6) Power Point (7) 3 (8) HP HP HP (9) 1 HP (10) Excel (11) 2 (12) Excel (13) 3 (1) (2) (1) (1) (2) (3) (4) (1) (2) (3) (4) (1) (2) (3) (4) (5) (6)

volunteer_kobe

1 2 2 3 4 15 80 i 3 8 8 14 18 21 25 35 35 40 44 53 59 59 64 66 72 81 84 86 1 1 88 ii 90 92 94 55 96 101 102 104 106 108 110 112 113 114 115 118 120 122 124 126 130 132 133 134 135 136 138 139 140 141 145

untitled

COLAK Mehmed 11000 305 305 180 10000 9000 8000 160 140 120 7000 100 6000 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 80 GH IGF-1 GH GH 5 4 3 2 1 0 2 3 4 5

加藤茂孝先生

Shigetaka KATOW 2009 4 24 WHO 5 9 1 5 16 1 TV 6 12 6 11 WHO 6 4 5 12 E-mail : modern_media@eiken.co.jp 2009. 4. 28. http:idsc.nih.go.jpidwrkanjaweeklygraph01flu.html 0101-0051 - RIKEN Center of Research

0.01mg/ ç 0.01 mg/ ç 0.01 mg/ ç 0.01 mg/ ç 0.05 mg/ ç 0.05 mg/ ç 0.01 mg/ ç 0.01 mg/ ç 0.0005mg/ ç 0.0005mg/ ç 0.02 mg/ ç 0.02 mg/ ç 0.002 mg/ ç 0.002 mg/ ç 0.004 mg/ ç 0.004 mg/ ç 0.02 mg/ ç 0.02 mg/

AAS48.indd

Suzuki K. (2016). Breeding for disease resistance to Mycoplasma pneumonia of swine All about SWINE 48, 2-12 PRDC ARMPS PRRS 18 1 21 24 32 40 MPS EU 2006 2011 SPF 2 3 MPS 5 MPS 4 MPS MPS MPS 2 MPS MPS MPS

32 100 34 51 16,300

32 100 34 51 16,300 - 7 - - 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 1 3 3 5 5 B 6 2 2 4 4 6 10 - - 8 - - - 9 - 20 80 1/3 - - 10 - 0.7 0.9kg 21 147 70-11 - - 50 10cm 50 100 30cm kg 100

6_総説特集（池）.indd

Journal of Environmental Biotechnology Vol. 15, No. 2, 71 75, 2016 総説 ( 特集 ) セレン代謝微生物を利用したセレン含有排水処理技術の開発 Development of Selenium-Containing Wastewater Treatment Technologies Using Microbial Selenium Transformation

Fig. ph Si-O-Na H O Si- Na OH Si-O-Si OH Si-O Si-OH Si-O-Si Si-O Si-O Si-OH Si-OH Si-O-Si H O 6

NMR ESR NMR 5 Fig. ph Si-O-Na H O Si- Na OH Si-O-Si OH Si-O Si-OH Si-O-Si Si-O Si-O Si-OH Si-OH Si-O-Si H O 6 Fig. (a) Na O-B -Si Na O-B Si Fig. (b) Na O-CaO-SiO Na O-CaO-B -Si. Na O-. CaO-. Si -. Al O

近畿中国四国農業研究センター研究報告　第７号

230 C B A D E 50m 558 0 1km (mg L 1 ) T N NO 2 3 N NH 4 N 2.0 0 (a) 2001 1.5 6 20 21 5 1.0 0.5 0.0 2.0 1.5 1.0 0.5 0.0 14:00 17:00 (b) 2001 7 3 4 20:00 23:00 2:00 (h) 5:00 8:00 11:00 10 0 5 10 15

会報35号表紙.pdf

35 No. (2017 1 ) RNA 2017 2017 TV 365 365 chunky 26 RNA 2017 Congratulations26 30-1 - RNA 2017-2 - - 3 - - 4 - - 5 - - 6 - 2016 8 31 9 2 RNA 2016 1 RNA RNA RNA RNA RNA 1-7 - RNA RNA 3 3 7 31 RNA ncrna

yakugaku-kot.ppt

2009 Masaaki Kotera kot@kuicr.kyoto-u.ac.jp 2 I II / A () B1 () B2 B12 C () D A D () () () () DNA 5- http://www.genome.jp/kegg/pathway.html KEGG PATHWAY Database Xenobiotics biodegradation http://www.genome.jp/kegg/pathway.html

() ( 2 1)90 (2010) ( 1) QIAGEN DNeasy Blood & Tissue Handbook FAVORGEN Tissue Genomic DNA Extract

2012 (Sekiya et al 2012) ( ) ( 1) 1 1. 2010 2012 2013 2014 6 () 2014 8 29 481 ( 2 1)90 (2010) 461 20 5 5 35 ( 1) QIAGEN DNeasy Blood & Tissue Handbook FAVORGEN Tissue Genomic DNA Extraction Mini Kit DNA

9_総説一般（高畑）.indd

Journal of Environmental Biotechnology Vol. 13, No. 2, 111 116, 2013 総説 ( 一般 ) ベンゼン汚染土壌 地下水の好気的及び嫌気的バイオレメディエーション技術の開発 Development of the Aerobic and Anaerobic Bioremediation Techniques for Benzene-contaminated

14 15 12 17 3 24 iii 1 1. 1 1 1. 2 1 1. 3 2 1. 4 3 2 2. 1 6 2. 2 7 2. 2. 1 7 2. 2. 2 12 3 3. 1 14 3. 2 15 4 4. 1 17 4. 2 17 4. 2. 1 17 4. 2. 2 17 4. 2. 3 20 4. 2. 4 22 4. 2. 5 25 4. 3 25 4. 3. 1 25 4.

ッ ー ー ー() () 2.5 () () 21 1) -1 2) -2 10 m 5 7 23 6 1)2) 3) -1-2 H23.4.25 -15-20 4 75 5 1) -1 (5) (3) (3) (2) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) 1) ( 23 6 8 ) 2) 22 3)

論文

*, 1 1 Selection of superior Frankia spp. for rapid cultivation of Alnus hirsuta seedlings Maki Saito *, 1 and Mikio Hasegawa 1 4 2 4 28 9 30 cm 30 cm 70 % 5 Abstract: In order to develop the rapid cultivation

広島総技研畜技セ研報 Bull,Hiroshima Pref. Tech.Res.Ins. Livest.Tech.Res.Cent. ISSN 広島県立総合技術研究所 畜産技術センター研究報告 Bulletin Hiroshima Prefectural Technology

広島総技研畜技セ研報 Bull,Hiroshima Pref. Tech.Res.Ins. Livest.Tech.Res.Cent. ISSN 1882-4862 広島県立総合技術研究所 畜産技術センター研究報告 Bulletin Hiroshima Prefectural Technology Research Institute Livestock Technology Research Center

(2009) 1... / 1 ( ) / 1 ( ) / 1 ( ), 2 ( )

212009................................................ 2............................................ 115 (2009) 1... / 1 ( )........................................... 4 2... / 1 ( )......................................

Fig. 4. Configuration of fatigue test specimen. Table I. Mechanical property of test materials. Table II. Full scale fatigue test conditions and test

(J. Soc. Mat. Sci., Japan), Vol. 52, No. 11, pp. 1351-1356, Nov. 2003 Fatigue Life Prediction of Coiled Tubing by Takanori KATO*, Miyuki YAMAMOTO*, Isao SAWAGUCHI** and Tetsuo YONEZAWA*** Coiled tubings,

13 2, ,

1 1 () () 13 2,338 50 13 381 96.7 149 94.9 130 94.2 52 88.1 47 123.6 14 33,600 50.9 10 280 120.0 14 57 1. 50 18 32 50100 9 16 101200 13 23 201 17 30 50 201 2. 43 75 3. 65 4. 5. 90 6. 7. 8. 9. 30 2526 27

新たな基礎年金制度の構築に向けて

[ ] 1 1 4 60 1 ( 1 ) 1 1 1 4 1 1 1 1 1 4 1 2 1 1 1 ( ) 2 1 1 1 1 1 1 1996 1 3 4.3(2) 1997 1 65 1 1 2 1/3 ( )2/3 1 1/3 ( ) 1 1 2 3 2 4 6 2.1 1 2 1 ( ) 13 1 1 1 1 2 2 ( ) ( ) 1 ( ) 60 1 1 2.2 (1) (3) ( 9

180126_TOO_ウイルス感染症研究者向け資料【最終】.indd

ウイルス 感染症研究 実験特集 不可能を可能にする NanoLuc テクノロジー NanoLuc テクノロジーをご利用のウイルス 感染症研究に携わるユーザー 4 名の方に最新の 研究成果についてご寄稿頂きました プロメガが開発した NanoLuc は 19 KDa の低分子の発光酵素であり 従来のホタルルシフェラーゼの 1/3 の分子量であるにもかかわらず 発 光レベルは 1 倍にも達します この

untitled

I 3 2 4 2. 4 2. 2 4 2. 3 4 2. 4 4 2. 5 4 2. 6 4 2. 7 5 2. 8 5 2. 9 5 3. 8 3. 8 3.2 8 3.3 0 3.4 0 3.5 4 3.6 6 3.7 7 3.8 Lagmur 22 3.9 Freudlch 26 3.0 29 3. 30 3.2 36 4. 37 4. 37 4.2 37 4.3 39 4.4 4 5. DNA

< > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ [ [ [ [ KULASIS

< > Introduction to Basic Organic Chemistry 1,2 [ 2 [ 10 11 12 13 14 15 [ [ [ [ KULASIS < > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ 11 12 14 15 [ [ [ [ KULASIS < > Introduction to Basic

1

日本組織適合性学会誌第23巻2号

Major Histocompatibility Complex 2016; 23 (2): 115 122 HLA 1 1) 1) HLA MHC 1900 HLA HLA キーワード : HLA HLA HLA HLA 2 HLA HLA HLA 3 1 1 HLA HLA 図 1 2016 6 30 2016 8 2 105 0013 1 10 14 3 5 TEL: 03 5776 0048

H

Analysis of Hypoxia Dynamics Using Pelagic and Benthic Biogeochemical Model: Focus on the Formation and Release of Hydrogen Sulfide Masayasu IRIE, Shu

Analysis of Hypoxia Dynamics Using Pelagic and Benthic Biogeochemical Model: Focus on the Formation and Release of Hydrogen Sulfide Masayasu IRIE, Shuzo NISHIDA, Kyosuke TERANAKA, Yohei TSUJI Mitsunari

Microsoft Word - 本論文の代替用要旨（2_19_馬場保徳）.doc

1 1 5% [1]2011 [2] [3][4] [5] [6] [7-8] 2 3 4 2 5 BDF 9000 kl [9] [7-8, 10-11] 50 m 3 30 m 3 -working vol. 3.5 m 3 -week 5 75L glycerol/plant-day 30 L glycerol/plant-day (1 ml/l-day)fig. 1 106% 70 85%

ab c d 6 12 1:25,000 28 3 2-1-3 18 2-1-10 25000 3120 10 14 15 16 7 2-1-4 1000ha 10100ha 110ha ha ha km 200ha 100m 0.3 ha 100m 1m 2-1-11 2-1-5 20cm 2-1-12 20cm 2003 1 05 12 2-1-13 1968 10 7 1968 7 1897

2016/17 P 1 P 8 P13 P18 P23 P28 7 P33 P41 15 P48 P65 GC-MS/MSLC-MS/MS 2016/17 2016 48 1.00 AH3 75.4% HI AH1pdm09 B AH3 D151GD151N HA AH1pdm09 AH3 B 5000 500 2016/17-1 - 2016 2017 78 24 well MDCKLLC-MK2HEp-2HeLa

catalog_handle.pdf

Nagasawa Standard Product Lever Handle 02 03 INDEX II FG FS MG MS MU MU MG MS MU WB WB GT SB BGT BWB WB HG GB GT AB WB AB HG BGT BWB FG FS CS BL WB GB BGT GN BWB SN MG BM AB BG BN MS NB HG BHG MU GT SB

1990 preimplantation genetic diagnosis: PGD ( )

Title Author(s) 日本における受精卵診断をめぐる論争 (1990 年代 ) - 争いの経過 - 利光, 恵子 Citation 医療 生命と倫理 社会. 7 P.67-P.85 Issue Date 2008-03-20 Text Version publisher URL https://doi.org/10.18910/12560 DOI 10.18910/12560 rights

Isotope News 2017年10月号　No.753

Ishioka Noriko ₁ はじめに RI RI RI RI ₂ 悪性褐色細胞腫と治療の現状 3,000 90 I meta- Iiodo-benzylguanidine I-MIBG 1 ₃ α 線の標的アイソトープ治療 2016 6 223 RaCl2 223 Ra 223 Ra 14 表 1 α 線と β 線の違い -decay (42%) Eα = 5.9 MeV At 7.2 h EC

CHEMOTHERAPY

CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin

< > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ [ [ [ [ KULASIS

< > Introduction to Basic Organic Chemistry 1,2 [ 2 [ 10 11 12 13 14 15 [ [ [ [ KULASIS < > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ 11 12 14 15 [ [ [ [ KULASIS < > Introduction to Basic

生物

Biology 115-470 115-419 60 SERIES 114-171 114-170 114-172 114-029 114-138 61 114-372 114-370 62 Biology K22486-000 K22435-000 K22486-010 144-300 K22467-000 63 64 144-200 244-115 248-150 144-190 144-195

untitled

Letter561.pdf

http://nibs.lin.gr.jp/ 2 18 1 5 56 2 2010 3 19 50 A 2007 10 45 60 2007 12 30 2008 1 31 A 2 1 1 2 3 4 5 6 2 PCV2 7 PCV2 in situ 8 9 PCV2 [1, 2] PCV2 PCVAD 1. Jensen, T. K., Vigre, H., Svensmark, B. and

25 6 7 X (crystallizing ligand) Fv Fv 3.5 Co-crystallization of membrane proteins with antibody fragments may emerge as a general tool to facilitate crystal growth and improve crystal quality. The bound

2003 10 2003.10.21 70.400 YES NO NO YES YES NO YES NO YES NO YES NO NO 20 20 50m 12m 12m 0.1 ha 4.0m 6.0m 0.3 ha 4.0m 6.0m 6.0m 0.3 0.6ha 4.5m 6.0m 6.0m 0.6 1.0ha 5.5m 6.5m 6.0m 50m 18 OK a a a a b a

9 Nippon Shokuhin Kagaku Kogaku Kaishi Vol. /,, No.0,,/+,/0 (,**/) 251 * * E#ects of Microbial Transglutaminase on Melting Point and Gel property of G

9 Nippon Shokuhin Kagaku Kogaku Kaishi Vol. /,, No.0,,/+,/0 (,**/) 251 * * E#ects of Microbial Transglutaminase on Melting Point and Gel property of Gelatins Takahiko Soeda, Tomoko Kaneko*, Akiko Hokazono,

2(2) / (1) (1) -2

1(1) -1 2(2) / (1) (1) -2 3(2) (2) (3) (4) (5) -3 4(1) 1 1-4 5(2) 2-1 -5 6(1) (1) (1) (2) (2) -6 7(2) (1) -7 8-8 9-9 10-10 11 (1) -11 12(1) -12 13(2) -13 14(3) -14 15-15 BOD CH4 COD DO EIA GDP GRP JICA

A(6, 13) B(1, 1) 65 y C 2 A(2, 1) B( 3, 2) C 66 x + 2y 1 = 0 2 A(1, 1) B(3, 0) P 67 3 A(3, 3) B(1, 2) C(4, 0) (1) ABC G (2) 3 A B C P 6

1 1 1.1 64 A6, 1) B1, 1) 65 C A, 1) B, ) C 66 + 1 = 0 A1, 1) B, 0) P 67 A, ) B1, ) C4, 0) 1) ABC G ) A B C P 64 A 1, 1) B, ) AB AB = 1) + 1) A 1, 1) 1 B, ) 1 65 66 65 C0, k) 66 1 p, p) 1 1 A B AB A 67

Key words : influenza, nested-pcr, serotype

Key words : influenza, nested-pcr, serotype Table 1 Sequence of PCR primers used to detect HA gene of influenza virus 524 清水 Fig. 1 Detection of PCR product 英明 他 (lstpcr) Table 2 Results method Fig. 2

000_013_.....qx4

569 n STEPHENSON, 1945 ; JOHNSTON, 1959 ; BANAGE and VISSER, 1965 ; NORTON, 1978 ; CHITWOOD, 22 ; BANSAL and BAJAJ, 23 ; BROWNING et al., 24 ; MCELDERRY et al., 25 LINFORD et al., 1938 ; JOHNSON et al.,

精神障害者

13 ACT 156-8585 2-1-8 TEL03-3304-5701 14 10 30 ACTassertive community treatment 1 ACT ACT ACT ACT Fidelity ScaleACT ACT ACT ACT ACT Fidelity 2000, 2001; 1994 Tessler & Gamache 2000 14 1 2002 1986 1994

＜２００３年分東京医科歯科大学産科婦人科学教室業績＞

1.Obayashi S, Aso T, Sato J, Hamasaki H, Azuma H: Intimal hyperplasia in human uterine arteries accompanied by impaired synergism between prostaglandin I2 and nitric oxide. British Journal of Pharmacology

漸化式のすべてのパターンを解説しましたー高校数学の達人・河見賢司のサイト

https://www.hmg-gen.com/tuusin.html https://www.hmg-gen.com/tuusin1.html 1 2 OK 3 4 {a n } (1) a 1 = 1, a n+1 a n = 2 (2) a 1 = 3, a n+1 a n = 2n a n a n+1 a n = ( ) a n+1 a n = ( ) a n+1 a n {a n } 1,

1. - - - 2 - - 3 - - 4 - 1 Muser KT, Bond GR, Drake RE, et al(1998). Model of community care for severe mental illness: A review of research on case management. Schizophrenia Bulletin, 24(1): 33-74. -

1 2 3 4 4.1 4.2 4.3 4.4 4.5 1

18 1 2 3 4 4.1 4.2 4.3 4.4 4.5 1 1 2 140 100 10 30 16 2 2 2 195070 GIS 17 6 9 6 16 6 29 7 20 1 8 31 9 2 9 21 10 19 12 14 2 9 1 100 2 1112 18 5 31 8 110 11 2931 12 13 4 12 25 2 23 5 () 3 19 2 200 3 3.1

- 108 -

3-107- - 108 - 3.1 3.1.1 3.1.2 3.1.2.1 5 LD50 LC50 ATE 3.1.1 1 2 3 4 5 (mg kg ) 5 50 300 2000 5000 a (mg kg ) 50 200 1000 2000 a (ppm) 100 500 2500 5000 a b mg 0.5 2.0 10 20 a b c d 0.05 0.5 1.0 5 (mg

untitled

ORYZA POLYAMINE ORYZA POLYAMINE -P -PC -LC 1. Ver.1.0 MM ver. 1.0MM 1) Roseeuw D.I. et al., Epidermal keratinocytes actively maintain their intracellular polyamine levels. Cell Tissue Kinet. 16, 493-504

1 3 2 4 1983 2 1979 04 1 03 GDP 9.1% 1 GDP 1,000 04 3 10 04 01 12 WTO WTO 4 3 3 1979 1973 1974 1978 1978 11 1979 1982 1982 1984 1988 1989 1989 1998 SEPA 5 1979 1989 3 1,000 9 SEPA 10 1982 6 5 5 6 1993

2NIBS CSK 3 20kg NIBS SLA DRBI(D/DDQA(D/D DQBSO9 S10/S10 Table ,2 E 1 2 1,2,5 2,5 15

食用以外に利用される豚について 齋藤敏樹 ( 日本生物科学研究所 ) Saitoh, T. (2009). Nutlization of a swine other than food ALL about SWINE 35, 14-20 1 2 3 3 12 160 180 kg 12 60 80 kg 12 30 kg NIBS Fig. 1 1995 2007 Table 1 2007 1,300

Letter566.pdf

http://nibs.lin.gr.jp/ 2 2 29 1000 1990 27.4 30.0 2009 13.5 49.6 1995 475 87 2009 292 332 1995 54 22 2009 70 101 57 1 2011 3 3 13 2008 3 2009 5 11 6 4.5 2 cm 3 1 1 2 3 S 100 4 Vimentin Melan A 5 3 HE Canine

タミフルインタビューフォーム

2008 1 20 87625 IF 1998 9 75 3% 2 1 75mg 1 g 30mg Oseltamivir Phosphate 2000 12 12 2001 2 2 2001 2 2 2002 1 17 2002 4 26 2002 7 31 IF 2008 1 O H 2 N O H O CH 3 H 3 C N H H 3 PO 4 H H O H 3 C CH 3

JANTI-SANE-03 WG 1. 1.1 197166.817km 16km23km 743 1-1 A, As 1-11-2, 1-3 3760 2981 79.3 1.2 189 Ss Ss S 1-4,5 1-2 1-1 30km 10km Google ZENRIN 1-1 As 1 A 1 B C *1: 2006 1-2 1-2 1-3 1-3 Ss 1-4 6 H21. H21.6/19

untitled

19 m 3 m 3 m 3 /s m 3 3 m 3 m 3 m 3 m 3 m 3 m 3 m 3 2km 2km 4km 3km 2km 2km 16km () 2km 2km 4km 4km 2km 2km 16km m 3 m 3 m 3 264,970 m 3 1,209.6 m 3 36,850 m 3 1,728 m 3 m 3 m 3 m 3 m 3 m 3 m 3 m

日本消化器外科学会雑誌第29巻第9号

Table 1 Oligonucleotide primers used for RT-PCR and internal probes used for Southern blot hybridization Cytokine Primer Sequence (5'-3') 5' 3' Internal probe s' 3' Internal probe 5' 3' Internal probe

訪問看護ステーションにおける安全性及び安定的なサービス提供の確保に関する調査研究事業報告書

1... 1 2... 3 I... 3 II... 3 1.... 3 2....15 3....17 4....19 5....25 6....34 7....38 8....48 9....58 III...70 3...73 I...73 1....73 2....82 II...98 4...99 1....99 2....104 3....106 4....108 5.... 110 6....

ISO

ISO ISO ISO(International Standardization Organization) 135 ISO CD(Committee Draft) DIS(Draft for International Standard) FDIS(Final DIS) ISO ISO23500 2004.01.13 ANSI/AAMI RD52 2004.04.13 6 2004.08.09

14 88 7 1 3 4 75 14 9 13 51 16 22 16 69 22 134 54 40 27 5 29 29 3 31 11 2-1 - 12 22 20 150 200 4.1993 22 22 250 400 2011 576 2011 2 2010 2 3 3 4 77 1990 448 1,298 3 2-2 - 1990 7 5,000 100 5 8 1996 75 85

... - 1 -... - 1 -... - 1 -... - 1 -... - 1 -... - 1 -... - 1 -... - 1 -... - 3 -... - 4 -... - 4 -... - 4 -... - 5 -... - 6 -... - 6 -... - 6 -... - 6 -... - 6 -... - 7 -... - 7 -... - 7 -... - 7 -...

untitled

1 2 3 4 5 (1834) 1834 200 6 7 8 9 10 11 (1791) (17511764) (1824) 1843 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 (1791) (1791) (17511764) (17511764) (1824)1843

yasi10.dvi

2002 50 2 259 278 c 2002 1 2 2002 2 14 2002 6 17 73 PML 1. 1997 1998 Swiss Re 2001 Canabarro et al. 1998 2001 1 : 651 0073 1 5 1 IHD 3 2 110 0015 3 3 3 260 50 2 2002, 2. 1 1 2 10 1 1. 261 1. 3. 3.1 2 1

2 (1) (2) SCI 2 SCI 2 24 2 12 2

2004 (1) (2) (2) (3) (1) 1 (2) (3) 2 (1) (2) SCI 2 SCI 2 24 2 12 2 100% / 16 2002 2003 http://lin.lin.go.jp/alic/month/dome/1997/nov/chousa.htm (05 612 1315 1618 1922 2329 3039 4049 5059 60 ) =10 b g 1

dsample.dvi

1 1 1 2009 2 ( ) 600 1 2 1 2 RFID PC Practical Verification of Evacuation Guidance Based on Pedestrian Traffic Measurement Tomohisa Yamashita, 1 Shunsuke Soeda 1 and Noda Itsuki 1 In this paper, we report

CHEMOTHERAPY JUNE 1986

VOL. 34 S-3 CHEMOTHERAPY Fig. 1 Structural formula of L-105 CHEMOTHERAPY JUNE 1986 VOL. 34 S-3 CHEMOTHERAPY Table 1 Antibacterial spectra of L-105 against gram negative anaerobic rods Inoculum 106 cells/ml

01NGRCnewsNo4.indd

NGRC No. 4 ... 4... 5... 67... 8... 9... 10 DNA... 11... 12... 13... 14 Mixia osmundae... 15... 16 24... 17... 1828... 2932 1 DDBJ 2012 5 2 1 SNP 2 Zhao et al., 2010 3 A B 4 1 1 1 2 1 DNA 1 2EMS Mutator

http://keirin.jp ...1 1....2 1.1...2 1.1.1...2 1.1.2...4 1.2...5 1.2.1...6 1.2.2...7 1.3...11 1.3.1...11 1.3.2...12 2....14 2.1...14 2.2...17 2.2.1 5...17 2.2.2...20 3....27 3.1...27 3.1.1...27 3.1.2...35

19) Pearson, J., Southam, G. G. and Holley, R. A.: Survival and transport of bacteria in egg washwater. Appl. Environ. Microbiol., 53, 2060-2065 (1987). 20) Poovaiah, B. W.: Role of calcium in prolonging

JAPAN MARKETING JOURNAL 111 Vol.28 No.32008

Vol.28 No.32008 JAPAN MARKETING JOURNAL 111 Vol.28 No.32008 JAPAN MARKETING JOURNAL 111 Vol.28 No.32008 JAPAN MARKETING JOURNAL 111 Vol.28 No.32008 JAPAN MARKETING JOURNAL 111 Vol.28 No.32008 JAPAN MARKETING

JAPAN MARKETING JOURNAL 113 Vol.29 No.12009

JAPAN MARKETING JOURNAL 113 Vol.29 No.12009 JAPAN MARKETING JOURNAL 113 Vol.29 No.12009 JAPAN MARKETING JOURNAL 113 Vol.29 No.12009 JAPAN MARKETING JOURNAL 113 Vol.29 No.12009 Vol.29 No.12009 JAPAN MARKETING

JAPAN MARKETING JOURNAL 110 Vol.28 No.22008

Vol.28 No.22008 JAPAN MARKETING JOURNAL 110 Vol.28 No.22008 JAPAN MARKETING JOURNAL 110 Vol.28 No.22008 JAPAN MARKETING JOURNAL 110 Vol.28 No.22008 JAPAN MARKETING JOURNAL 110 Vol.28 No.22008 JAPAN MARKETING

UNEP sustainable consumption sustainable production 1980 rebound effect rebound effect IO-EHA 1 CO 2 rebound effect CO 2 rebound effect

2005 3 Discussion Paper No. 95 UNEP sustainable consumption sustainable production 1980 rebound effect rebound effect IO-EHA 1 CO 2 rebound effect CO 2 rebound effect 2005 3 1 (Environmental Household

23 3 11 14 46 9.0 7 10m 40.1m 15,883 2,681 25 4 10 39 40 800 180 24 2425 22 21 24 5 3 21 24 10,899 20,472 13,723 33,007 667 400 79,167 8,620 11,694 10,089 25,131 690 215 56,439 13,614 20,897 15,200 32,213

[ml] 180 160 140 120 100 80 60 40 20 0 Cumulative biogas production [ml/mg-input VS] 0 10 20 30 40 50 60 [] 1 0.8 0.6 0.4 0.2 0 dog food PLA foam 0 10 20 30 40 50 days RUN1-1 RUN1-2 RUN2-1 RUN2-2 RUN3-1

The Evaluation of LBB Behavior and Crack Opening Displacement on Statically Indeterminate Piping System Subjected to Monotonic Load The plastic collap

The Evaluation of LBB Behavior and Crack Opening Displacement on Statically Indeterminate Piping System Subjected to Monotonic Load The plastic collapse and LBB behavior of statically indeterminate piping

Web Stamps 96 KJ Stamps Web Vol 8, No 1, 2004

The Journal of the Japan Academy of Nursing Administration and Policies Vol 8, No 1, pp 43 _ 57, 2004 The Literature Review of the Japanese Nurses Job Satisfaction Research Which the Stamps-Ozaki Scale

1 (1) vs. (2) (2) (a)(c) (a) (b) (c) 31 2 (a) (b) (c) LENCHAR

() 601 1 () 265 OK 36.11.16 20 604 266 601 30.4.5 (1) 91621 3037 (2) 20-12.2 20-13 (3) ex. 2540-64 - LENCHAR 1 (1) vs. (2) (2) 605 50.2.13 41.4.27 10 10 40.3.17 (a)(c) 2 1 10 (a) (b) (c) 31 2 (a) (b) (c)

Ⅰ

20 20 2007 19 2008 20 13 3 21 12 26 6 28 9 36 7 46 4 48 4 57 4 3 15 4 18 4 7 5 3 3600 120m 130 20 32 51 20 4 3 1 1 3 8 17 3 9-1 - ha 37.7 5.2 14.3 1.6 13.7 3.1 1.4 2,052mm 31.9 0.3 15.4 ph 6.3H 2 O 2750

平成１３年度内分泌攪乱化学物質のヒトへの健康影響調査研究報告書

. 1,3 4 5. 1 2 NB-1 MCF7 MEIC 1-3 4-6 NB-1 JCRB Japan Cancer Research Bank MCF ATCCAmerican Type Culture Collection 2 19994 212 11 PVDF.22µm 8 2 11 4 4 3 5 1 4 cellsml -1 96 4,6 NB-1 48 MCF7 24 4 5 48

> > <., vs. > x 2 x y = ax 2 + bx + c y = 0 2 ax 2 + bx + c = 0 y = 0 x ( x ) y = ax 2 + bx + c D = b 2 4ac (1) D > 0 x (2) D = 0 x (3

13 2 13.0 2 ( ) ( ) 2 13.1 ( ) ax 2 + bx + c > 0 ( a, b, c ) ( ) 275 > > 2 2 13.3 x 2 x y = ax 2 + bx + c y = 0 2 ax 2 + bx + c = 0 y = 0 x ( x ) y = ax 2 + bx + c D = b 2 4ac (1) D >

1 (1) (2)

1 2 (1) (2) (3) 3-78 - 1 (1) (2) - 79 - i) ii) iii) (3) (4) (5) (6) - 80 - (7) (8) (9) (10) 2 (1) (2) (3) (4) i) - 81 - ii) (a) (b) 3 (1) (2) - 82 - - 83 - - 84 - - 85 - - 86 - (1) (2) (3) (4) (5) (6)

- 2 -

- 2 - - 3 - (1) (2) (3) (1) - 4 - ~ - 5 - (2) - 6 - (1) (1) - 7 - - 8 - (i) (ii) (iii) (ii) (iii) (ii) 10 - 9 - (3) - 10 - (3) - 11 - - 12 - (1) - 13 - - 14 - (2) - 15 - - 16 - (3) - 17 - - 18 - (4) -

2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1

1 1979 6 24 3 4 4 4 4 3 4 4 2 3 4 4 6 0 0 6 2 4 4 4 3 0 0 3 3 3 4 3 2 4 3? 4 3 4 3 4 4 4 4 3 3 4 4 4 4 2 1 1 2 15 4 4 15 0 1 2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4

ＰＲ映画-1

II III I ~ 2 ~

中堅中小企業向け秘密保持マニュアル

20 15 14.6 15.3 14.9 15.7 16.0 15.7 13.4 14.5 13.7 14.2 10 10 13 16 19 22 1 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 2,500 59,862 56,384 2,000 42,662 44,211 40,639 37,323 1,500 33,408 34,472

1 47 200 300 1 1 25172005 1

8... 1... 24... 55 3... 75... 93 17 2005 1 47 200 300 1 1 25172005 1 8 pdf 1 2 9 1812 6 3 1832 11 7 1836 1 2 2 4 9 1997 2 2 101813 1 1 9 5 4 7 3 12 3 4 7 10 6 3 10 6 3 12 5 3 A 10 5 B 4 C 10 7 D 3 E 5